SNS 기사보내기
Migraine is a disabling condition that not only impairs an individual's quality of life, but also causes societal losses. Therefore, it is important to treat migraine quickly and preventively. Expectations are higher than ever for Aquipta (atogepant), an oral CGRP treatment that is effective in preventing migraine and easy to take.
This was evident at “AbbVie's Migraine Portfolio: from CM to EM Symposium,” held at the Grand InterContinental Seoul Parnas on March 6.
AbbVie's Migraine Portfolio: from CM to EM Symposium at the Grand InterContinental Seoul Parnas on March 6, 2025.
AbbVie's Migraine Portfolio: from CM to EM Symposium at the Grand InterContinental Seoul Parnas on March 6, 2025.
The symposium, organized by AbbVie Korea to share the latest advances in migraine prophylaxis and foster academic exchange among experts, was attended by more than 100 neurologists both online and offline.
In her presentation, “Innovations in Migraine Treatment: The Latest Findings on the Disease and Atozepant,” Lee Mi-ji, a professor in the Department of Neurology at Seoul National University Hospital, presented the latest research on the recently revised migraine preventive treatment guidelines and the societal burden of migraine.
Lee shared interim results from the CAPTURE study, a Patient-Reported Outcome (PRO) study of migraine patients presented at the European Headache Society in December. The study showed that as migraine frequency increases, the impact on quality of life, as well as loss of productivity and disability in daily activities, is greater.
In particular, a post-hoc analysis of the phase 3 study evaluating the efficacy and safety of Aquipta in preventing migraine showed that the Aquipta 60 mg once-daily treatment group showed rapid improvement in AIM-D (physical activity and performance of functioning) as early as one week of treatment compared to the placebo group. This improvement was sustained for up to two to four weeks.
“Migraine is a serious condition that not only impairs the quality of life of patients, but also causes social losses, and needs to be managed with early treatment before it becomes chronic, as well as ongoing preventive care,” Lee said.
Kim Byung-kun, Professor of Neurology at Nowon Eulji Medical Center, presented “Management of patients with comorbidities due to migraine” and introduced various comorbidities that can occur in migraine patients and their treatment.
"As the frequency of headaches increases, the prevalence of migraine symptoms, impact and disability due to headaches, and comorbidities tend to increase," said Kim. "In particular, depression, a psychiatric comorbidity, is seen in many migraine patients and is strongly associated with the chronicity of migraine, so it is important to treat depression as soon as possible."
Moon Heui-soo, a professor of neurology at Kangbuk Samsung Hospital, spoke on “Changing Migraine Treatment Landscape,” highlighting the changes that the launch of Aquipta, an oral CGRP therapy, has brought to the migraine prevention treatment landscape.
"CGRP-targeted therapies, including Aquipta, are designed to target the pathophysiological mechanisms of migraine, unlike existing migraine preventive drugs, leading to innovative treatment changes." "Among them, Aquipta antagonizes CGRP receptors, showing a difference in mechanism of action from existing CGRP-targeted therapies. The rapid onset of action with no migraine in 87.7% of patients taking Aquipta 60 mg on day 1, the tolerability and safety profile confirmed in the study, and the benefits of an oral formulation have led to a change in the migraine treatment landscape in Korea, addressing an unmet need for migraine patients."
Furthermore, Aquipta's once-daily oral formulation, with a half-life of less than 11 hours and high patient preference for oral formulations, will help improve treatment planning and treatment adherence for migraine patients in the future, she added.
tweet
Related articles
Migraine is called ‘women's neurology’ because it disappears 2 years after menopause.
Korean neurologists express high expectations for AbbVie's migraine drug Aquipta
AbbVie's Aquipta effective in preventing migraine in patients who failed oral therapy
You Ji-young molly97@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited